WO2015138711A1 - Polypeptides visant à inhiber la protéine du virus d'epstein-barr bhrf1 et des protéines de la famille du lymphome à cellules b - Google Patents

Polypeptides visant à inhiber la protéine du virus d'epstein-barr bhrf1 et des protéines de la famille du lymphome à cellules b Download PDF

Info

Publication number
WO2015138711A1
WO2015138711A1 PCT/US2015/020155 US2015020155W WO2015138711A1 WO 2015138711 A1 WO2015138711 A1 WO 2015138711A1 US 2015020155 W US2015020155 W US 2015020155W WO 2015138711 A1 WO2015138711 A1 WO 2015138711A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
seq
amino acid
acid sequence
bcl
Prior art date
Application number
PCT/US2015/020155
Other languages
English (en)
Inventor
David Baker
Stephanie Ann BERGER
Geoffrey Y. BERGUIG
Erik PROCKO
Yifan SONG
Patrick S. Stayton
Original Assignee
University Of Wahington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Wahington filed Critical University Of Wahington
Publication of WO2015138711A1 publication Critical patent/WO2015138711A1/fr
Priority to US15/262,716 priority Critical patent/US9750814B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

L'invention concerne des polypeptides conçus pour se lier sélectivement à et inhiber la protéine du virus d'Epstein-Barr BHRFl et des protéines de la famille du lymphome à cellules B, ces polypeptides étant ainsi utiles pour le traitement de maladies liées au virus d'Epstein-Barr et du cancer.
PCT/US2015/020155 2014-03-12 2015-03-12 Polypeptides visant à inhiber la protéine du virus d'epstein-barr bhrf1 et des protéines de la famille du lymphome à cellules b WO2015138711A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/262,716 US9750814B2 (en) 2014-03-12 2016-09-12 Polypeptides to inhibit epstein barr viral protein BHRF1 and B cell lymphoma family proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461951988P 2014-03-12 2014-03-12
US61/951,988 2014-03-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/262,716 Continuation-In-Part US9750814B2 (en) 2014-03-12 2016-09-12 Polypeptides to inhibit epstein barr viral protein BHRF1 and B cell lymphoma family proteins

Publications (1)

Publication Number Publication Date
WO2015138711A1 true WO2015138711A1 (fr) 2015-09-17

Family

ID=52780042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/020155 WO2015138711A1 (fr) 2014-03-12 2015-03-12 Polypeptides visant à inhiber la protéine du virus d'epstein-barr bhrf1 et des protéines de la famille du lymphome à cellules b

Country Status (1)

Country Link
WO (1) WO2015138711A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9750814B2 (en) 2014-03-12 2017-09-05 University Of Washington Polypeptides to inhibit epstein barr viral protein BHRF1 and B cell lymphoma family proteins
WO2020018935A3 (fr) * 2018-07-19 2020-02-20 University Of Washington Conception de novo de commutateurs protéiques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002097094A1 (fr) * 2001-05-30 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research Sequences de facteur de modification de bcl-2 (bmf) et utilisation de celles-ci dans la modulation de l'apoptose

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002097094A1 (fr) * 2001-05-30 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research Sequences de facteur de modification de bcl-2 (bmf) et utilisation de celles-ci dans la modulation de l'apoptose

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHRISTIN TSE ET AL: "ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor", CANCER RESEARCH, AACR, US PHILADELPHIA, PA, vol. 68, no. 9, 1 May 2008 (2008-05-01), pages 3421 - 3428, XP002631072, ISSN: 1538-7445, DOI: 10.1158/0008-5472.CAN-07-5836 *
GEMMA L. KELLY ET AL: "An Epstein-Barr Virus Anti-Apoptotic Protein Constitutively Expressed in Transformed Cells and Implicated in Burkitt Lymphomagenesis: The Wp/BHRF1 Link", PLOS PATHOGENS, vol. 5, no. 3, 13 March 2009 (2009-03-13), pages e1000341, XP055189287, DOI: 10.1371/journal.ppat.1000341 *
JAMES L. LABELLE ET AL: "A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers", JOURNAL OF CLINICAL INVESTIGATION, vol. 122, no. 6, 1 June 2012 (2012-06-01), pages 2018 - 2031, XP055189510, ISSN: 0021-9738, DOI: 10.1172/JCI46231 *
L.-Y. LI ET AL: "Human cellular protein VRK2 interacts specifically with Epstein-Barr virus BHRF1, a homologue of Bcl-2, and enhances cell survival", JOURNAL OF GENERAL VIROLOGY, vol. 87, no. 10, 1 October 2006 (2006-10-01), pages 2869 - 2878, XP055189228, ISSN: 0022-1317, DOI: 10.1099/vir.0.81953-0 *
MARC KVANSAKUL ET AL: "Structural Basis for Apoptosis Inhibition by Epstein-Barr Virus BHRF1", PLOS PATHOGENS, vol. 6, no. 12, 23 December 2010 (2010-12-23), pages e1001236, XP055189601, DOI: 10.1371/journal.ppat.1001236 *
OLTERSDORF T ET AL: "an inhibitor of BCL-2 family proteins induces regression of solid tumours", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 435, 2 June 2005 (2005-06-02), pages 677 - 681, XP002491257, ISSN: 0028-0836, DOI: 10.1038/NATURE03579 *
PROCKO ERIK ET AL: "A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells", CELL, vol. 157, no. 7, 19 June 2014 (2014-06-19), pages 1644 - 1656, XP028874991, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2014.04.034 *
SHANGARY S ET AL: "Peptides derived from BH3 domains of Bcl-2 family members: A comparative analysis of inhibition of Bcl-2, Bcl-xL and Bax oligomerization, induction of cytochrome c release, and activation of cell death", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 41, no. 30, 30 July 2002 (2002-07-30), pages 9485 - 9495, XP002359834, ISSN: 0006-2960, DOI: 10.1021/BI025605H *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9750814B2 (en) 2014-03-12 2017-09-05 University Of Washington Polypeptides to inhibit epstein barr viral protein BHRF1 and B cell lymphoma family proteins
WO2020018935A3 (fr) * 2018-07-19 2020-02-20 University Of Washington Conception de novo de commutateurs protéiques
US10851135B2 (en) 2018-07-19 2020-12-01 University Of Washington De novo design of protein switches
CN112512544A (zh) * 2018-07-19 2021-03-16 华盛顿大学 蛋白质开关的全新设计

Similar Documents

Publication Publication Date Title
Procko et al. A computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein induces apoptosis in infected cells
JP6766194B2 (ja) ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
Berger et al. Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer
CN113498417B (zh) 多肽、其制备方法和用途
CA3008289A1 (fr) Inhibition de proteines sh2 induites par des cytokines dans des cellules nk
Orange et al. Cell penetrating peptide inhibitors of nuclear factor-kappa B
US20230036052A1 (en) Modified protein
WO2022089605A1 (fr) Globules rouges modifiés et utilisations correspondantes pour l'administration d'agents
Sintim et al. Interrupting cyclic dinucleotide-cGAS–STING axis with small molecules
CN115335064A (zh) 修饰的红细胞及其用于递送药剂的用途
WO2021231466A2 (fr) Compositions d'ace2 et méthodes
US20110158956A1 (en) Treating cancer
WO2015138711A1 (fr) Polypeptides visant à inhiber la protéine du virus d'epstein-barr bhrf1 et des protéines de la famille du lymphome à cellules b
US9750814B2 (en) Polypeptides to inhibit epstein barr viral protein BHRF1 and B cell lymphoma family proteins
US8927695B2 (en) Protein-based assays for screening of the IgE-receptor interaction
US11369662B2 (en) Methods of treating inflammation with monomeric CXCL12 peptide
WO2015175774A1 (fr) Lysostaphine désimmunisée et méthodes d'utilisation
Shrivastava et al. Plasmodium falciparum FIKK9. 1 is a monomeric serine–threonine protein kinase with features to exploit as a drug target.
WO2010118404A2 (fr) Procédés destinés à créer ou à identifier des composés se liant au facteur de nécrose tumorale alpha
US20200407401A1 (en) Compositions and methods for inhibition of alphavirus infection
US10766929B2 (en) De novo designed hemagglutinin binding proteins
Stumpp Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants
JP2022536797A (ja) 炎症性状態を処置するための方法および組成物
WO2023154841A2 (fr) Protéines synthétiques de neutralisation du sars-cov-2
Dalwadi Biochemical and structural characterization of the Elongator, TINTIN, and PI3K gamma complexes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15713283

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15713283

Country of ref document: EP

Kind code of ref document: A1